Dendritic cell-based therapy for mantle cell lymphoma

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1337-1343

  Munger, Corey M ^a   Vose, Julie M ^a   Joshi, Shantaram S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antigen priming; Cytotoxic T lymphocytes; Dendritic cells; Mantle cell lymphoma

Indexed keywords

CD18 ANTIGEN;

ANIMAL; ARTICLE; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LIVER TUMOR; LYMPHOCYTE ACTIVATION; MANTLE CELL LYMPHOMA; METHODOLOGY; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, CD18; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOMA, MANTLE-CELL; MICE; MICE, INBRED NOD; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 33747128614     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1337     Document Type: Article

References (32)

1. Kauh J, Baidas SM, Ozdemirli M and Cheson BD: Mantle cell lymphoma: clinicopathologic features and treatments. Oncology 17: 879-891, 2003.
2. Decaudin D: Mantle cell lymphoma: a biological and therapeutic paradigm. Leuk Lymphoma 43: 773-781, 2002.
3. Bertoni F, Zucca E and Cavalli F: Mantle cell lymphoma. Curr Opin Hematol 11: 411-418, 2004.
4. Lenz G, Dreyling M and Hiddemann W: Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 83: 71-77, 2004.
5. Zhu Y, Hollmen J, Katy R, Aalto Y, Nagy B, Elonen E, Kere J, Mannila H, Franssila and Knuutila KS: Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119: 905-915, 2002.
6. Staudt L, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185-197, 2003.
7. Gianni A, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C and Barbui T: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell allografting (R-HDS regimen). Blood 102: 749-755, 2003.
8. Hess G, Flohr T, Huber C, Kolbe K, Derigs H-G and Fischer T: Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplant 31: 775-782, 2003.
9. Andersen N, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K, Langholm R, Ralfkiaer E, Akerman M, Eriksson M, Kuittinen O and Geisler C: Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 71: 73-80, 2003.
10. Howard O, Gribben J, Neuberg D, Grossbard M, Poor C, Janicek M and Shipp M: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20: 1288-1294, 2002.
11. Lazzarino M, Arcaini L, Bernasconi P, Alessandrino E, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo A, Caltroni S, Iacona I, Regazzi M and Morra E: A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 116: 229-235, 2002.
12. Vandenberghe E, De Elvira C, Loberiza F, Lopez-Guillermo A, Conde E, Gisselbrecht C, Guilhot F, Vose J, van Biesen K, Rizzo J, Weisenburger D, Isaacson P, Horowitz M, Goldstone A, Lazarus H and Schmitz N: Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120: 793-800, 2003.
13. Whiteside T and Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53: 240-248, 2004.
14. O'Neill D, Adams S and Bhardwaj N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104: 2235-2246, 2004.
15. Delamarre L, Holcombe H and Mellman I: Presentation of exogenous antigens on major histocompatability complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 198: 111-122, 2003.
16. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H and Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27: 265-272, 2004.
17. Ribas A, Butterfield L, Glaspy J and Economou J: Current developments on cancer vaccines and cellular immunotherapy. J Clin Oncol 21: 2415-2432, 2003.
18. Gottfreid E, Krieg R, Eichelberg C, Andreesen R, Mackensen A and Krause W: Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immunity 2: 15-26, 2002.
19. Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P and Dalgleish AG: Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1500: 265-279, 2000.
20. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Yanik G, Levine J, Chang A, Braun T and Mule J: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61: 8513-8519, 2001.
21. Gilboa E and Vieweg J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199: 251-263, 2004.
22. Milazzo C, Reichardt VL, Muller MR, Grunebach F and Brossart P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101: 977-982, 2003. (Pubitemid 36139369)
23. Busca A, Bruno B, Boccadoro M, Locatelli F and Falda M: Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies. Med Sci Monit 8: RA221-RA232, 2002.
24. Hogan WJ and Deeg HJ: Stem cell transplantation: graft-mediated antileukemia effects. Methods Mol Med 109: 421-444, 2005.
25. Chakrabarti S and Childs R: Allogeneic immune replacement as cancer immunotherapy. Expert Opin Biol Ther 3: 1051-1060, 2003.
26. Grunebach F, Muller MR, Nencioni A and Brossart P: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 10: 367-374, 2003.
27. Wang P, Munger CM, Joshi AD, Pirruccello SJ and Joshi SS: Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res Treat 83: 15-23, 2004.
28. Siders W, Vergilis K, Johnson C, Shields J and Kaplan J: Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7: 498-505, 2003.
29. Takeda A, Homma S, Okamoto T, Kufe D and Ohno T: Immature dendritic cell/tumor cell fusions induce potent antitumor immunity. Eur J Clin Inv 33: 897-904, 2003.
30. Tanaka H, Shimizu K, Hayashi T and Shu S: Theraputic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220: 1-12, 2002.
31. Gowing H, Lawler M, Hagenbeek A, McCann S, Pamphilon D, Hudson J, van Weelden H, Braakman E and Martens C: Effect of ultraviolet-B light on lymphocyte activity and doses which normal bone marrow cells are preserved. Blood 87: 1635-1643, 1996.
32. Ek S, Ortega E and Borrebaeck CA: Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma. Leuk Res 29: 205-213, 2005.